Literature DB >> 7478543

Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer.

X Gao1, A Zacharek, D J Grignon, W Sakr, I J Powell, A T Porter, K V Honn.   

Abstract

We recently demonstrated a high frequency of loss of heterozygosity (LOH) at the D17S856 and D17S855 (within the BRCA1 gene) loci in primary prostate cancer, suggesting that the BRCA1 gene and/or other tumor suppressor gene(s) located within the interval of the D17S856 and D17S855 loci and/or within the vicinity of this interval may be important in prostate cancer (Cancer Res., 55: 1002-1005, 1995). To further define the exact boundary of the deleted region (i.e., D17S856/D17S855) and to detect other possible LOH regions on the long arm of chromosome 17, we analysed 23 matched normal and tumor DNAs with 15 polymorphic microsatellite markers spanning chromosome 17q12-21. Eleven of 22 (50%) informative tumors showed allelic deletion at one or more of the loci studied. A minimal area of LOH was identified to extend from the proximal boundary at the D17S776 locus to the distal boundary at the D17S855 locus, spanning an estimated < 2 Mb segment on chromosome 17q21. Our results suggest that a potential tumor suppressor gene(s) may reside in the < 2 Mb region centromeric (inclusive) to the BRCA1 gene and that this tumor suppressor gene(s) may be involved in the formation of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478543

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis).

Authors:  J A Doll; X Zhu; J Furman; Z Kaleem; C Torres; P A Humphrey; H Donis-Keller
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

2.  Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.

Authors:  J C Alers; P J Krijtenburg; A N Vis; R F Hoedemaeker; M F Wildhagen; W C Hop; T T van Der Kwast; F H Schröder; H J Tanke; H van Dekken
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  Familial prostate cancer and HOXB13 founder mutations: geographic and racial/ethnic variations.

Authors:  Henry T Lynch; Trudy G Shaw
Journal:  Hum Genet       Date:  2012-09-22       Impact factor: 4.132

4.  Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.

Authors:  K L Nastiuk; M Mansukhani; M B Terry; P Kularatne; M A Rubin; J Melamed; M D Gammon; M Ittmann; J J Krolewski
Journal:  Prostate       Date:  1999-08-01       Impact factor: 4.104

Review 5.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

6.  Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; Edson J Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

7.  Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer.

Authors:  J M Garcia; R Rodriguez; G Dominguez; J M Silva; M Provencio; J Silva; A Colmenarejo; I Millan; C Muñoz; C Salas; S Coca; P España; F Bonilla
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

8.  The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1.

Authors:  Yi-Chun Liao; Lizhen Si; Ralph W deVere White; Su Hao Lo
Journal:  J Cell Biol       Date:  2006-12-26       Impact factor: 10.539

9.  Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer.

Authors:  A Fosså; R Siebert; H C Aasheim; G M Maelandsmo; A Berner; S D Fosså; E Paus; E B Smeland; G Gaudernack
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

10.  Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.

Authors:  S Lehrer; F Fodor; R G Stock; N N Stone; C Eng; H K Song; M McGovern
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.